Fenspiride - CAS 5053-06-5
Catalog number: 5053-06-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Adrenergic Receptor | Histamine Receptor
Fenspiride is an α adrenergic and H1 histamine receptor antagonist. It is an oxazolidinone spiro compound. It is used as a drug in the treatment of certain respiratory diseases. It is also used for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract, as well as for maintenance treatment of asthma in Russia. It has been listed.
Publictions citing BOC Sciences Products
  • >> More
> 95%
Solid powder
Respiride;Viarespan;JP428;JP-428;NAT-333;NAT333;NDR-5998A;NDR5998A;Decaspiride;Espiran;8-(2-Phenylethyl)-1-oxa-3,8-diazaspiro(4.5)decan-2-one;1-Oxa-3,8-diazaspiro[4.5]decan-2-one, 8-(2-phenylethyl)-
Soluble in DMSO, not in water
-20°C Freezer
Fenspiride is used as a drug in the treatment of certain respiratory diseases. It is also used for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract, as well as for maintenance treatment of asthma.
Quality Standard:
In-house standard
Kilograms to Tons
Boiling Point:
126-127 °C | Condition: Press: 2 Torr
Melting Point:
1.19±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
Canonical SMILES:
Current Developer:
Fenspiride has been listed.
1.[The efficacy of application of fenspiride (erespal) for the treatment of exacerbation of bronchial asthma in children].
Lebedenko AA1, Mal'tsev SV. Vestn Otorinolaringol. 2011;(4):66-7.
The objective of the present study was to estimate the efficacy and safety of combination of anti-inflammatory treatment of bronchial asthma (BA) and therapy with erespal. A total of 57 children aged from 6 to 14 years were available for the observation. They presented with mild intermittent (n=27), mild persisting (n=20), and moderately severe (n=10) forms of the disease. The traditional treatment of all the patients was supplemented by daily intake of erespal syrup at a dose of 4 mg/kg b.w. from the first day after admission to the hospital. It is concluded based on the results of the study that the use of erespal reduces the duration of the disease and the time of recovery of bronchial patency; also, it accelerates the process of arterial blood saturation with oxygen.
2.[Pathogenetic correction of postoperative inflammation in modern rhinosurgery].
Kim IA, Nosulia EV. Vestn Otorinolaringol. 2010;(4):78-81.
This study included 20 patients presenting with polypous rhinosinusitis examined before and after endoscopic intervention in the nasal cavity and paranasal sinuses. Nitric oxide (NO) content in nasal secretion and polypoid tissue was estimated from the concentration of nitrates that, together with nitrites, are the final products of oxidation of nitric oxide and serve as markers of endogenous NO. Nitrates in the nasal secretion, endonasal mucosa, and polypous tissue were determined by the ionometric technique. Their content was additionally measured in 12 subjects without polypous rhinosinusitis. The nasal secretion and polypous tissue of PRS patients were found to contain nitrates at a higher concentration compared with healthy subjects. Nitrate concentrations in the nasal secretion and polypous tissue of PRS patients were not significantly different. Mean saccharine transport time in the nasal cavity of the patients with an elevated level of nitrates in the nasal secretion was significantly higher than in PRS patients with the lowered nitrate levels.
3.[The assessment of the effectiveness of fenspiride (erespal) for the combined treatment of the patients presenting with exudative otitis media].
Mel'chinskiĭ AN, Vasilenko DIu, Kiseleva GV. Vestn Otorinolaringol. 2013;(6):70-1.
The objective of the present work was to estimate the effectiveness and safety of combined anti-inflammatory therapy of exudative otitis media with the use of fenspiride (erespal). The study included 75 patients of whom 35 (group 1) were given standard therapy supplemented by erespal (80 mg thrice daily); the remaining patients receiving standard therapy alone formed group 2 (control). The patients treated with erespal reported the subjective improvement of hearing and reduced congestion on days 7 - 8. Similar changes in group 2 occurred on day 10. It is concluded that the use of erespal for the combined treatment of the patients presenting with exudative otitis media reduces the duration of hospital stay, accelerates recovery, and promotes rapid normalization of hearing.
4.[The use of eurespal for the treatment of chronic laryngitis].
Riabova MA. Vestn Otorinolaringol. 2011;(1):70-3.
The author provides a rationale for the use of eurespal for the treatment of chronic laryngitis based on the pathogenetic concept of pathological condition. The results of a clinical study designed to evaluate the efficiency and safety of eurespal therapy in patients with chronic laryngitis are presented.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Adrenergic Receptor Products

CAS 59-32-5 Halopyramine

(CAS: 59-32-5)

Halopyramine is known as a competitive reversible H1-receptor antagonist. It exerts its pharmacological action by competing with histamine for the H1 subtype hi...

CAS 3978-86-7 Azatadine dimaleate

Azatadine dimaleate
(CAS: 3978-86-7)

Azatadine is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively.

CAS 58-33-3 Promethazine hydrochloride

Promethazine hydrochloride
(CAS: 58-33-3)

Promethazine hydrochloride is first-generation antihistamine of the phenothiazine family used as an antiallergic, in pruritus, for motion sickness and sedation,...

CAS 147-24-0 Diphenhydramine HCl

Diphenhydramine HCl
(CAS: 147-24-0)

Diphenhydramine HCl (Benadryl), a histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a ...

CAS 6153-33-9 Mebhydroline Napadisylate

Mebhydroline Napadisylate
(CAS: 6153-33-9)

Mebhydroline Napadisylate is an antihistamine used for symptomatic relief of allergic symptoms caused by histamine release, including nasal allergies and allerg...

CAS 7361-61-7 Xylazine

(CAS: 7361-61-7)

Xylazine is an analogue of clonidine, which is an agonist at the α2 class of adrenergic receptor. It is a drug used for sedation, anesthesia, muscle relaxation ...

CAS 459168-41-3 JNJ-7777120

(CAS: 459168-41-3)

JNJ-7777120 is the first potent and selective non-imidazole histamine H4 receptor antagonist with Ki of 4.5 nM, exhibits >1000-fold selectivity over the other h...

CAS 562-10-7 Doxylamine Succinate

Doxylamine Succinate
(CAS: 562-10-7)

Doxylamine succinate competitively inhibits histamine at H1 receptors with substantial sedative and anticholinergic effects.

CAS 3964-81-6 Azatadine

(CAS: 3964-81-6)

Azatadine is a new antihistamine acts as histamine for histamine H1- receptor inhibitor ( IC50 = 6.5 nM and 10 nM, respectively).

CAS 65652-44-0 Pirbuterol acetate

Pirbuterol acetate
(CAS: 65652-44-0)

Pirbuterol acetate is a short-acting β2 adrenoreceptor agonist. It has bronchodilating action and is used as a bronchodilator. It is also used in the treatment ...

CAS 106133-20-4 Tamsulosin

(CAS: 106133-20-4)

Tamsulosin could block on the sympathetic α1 receptor, especially selectively bind to the α1A receptor and has been found to be effective in the treatment of be...

CAS 1027330-97-7 A 943931

A 943931
(CAS: 1027330-97-7)

A 943931 is a potent and selective histamine H4 receptor antagonist.

CAS 29122-68-7 Atenolol

(CAS: 29122-68-7)

Atenolol, with antianginal and antiarrhythmic properties, it is a cardioselective beta-adrenergic blocker and used in hypertension control.

CAS 63-12-7 P2647

(CAS: 63-12-7)

P2647, also known as Benzquinamide, is a discontinued antiemetic compound with antihistaminic, mild anticholinergic, and sedative properties. P2647 binds to the...

(CAS: 170686-12-1)

BMS-194449 was found to be a β-adrenergic receptor agonist that was once studied in antihyperglycaemics as well as obesity therapy.

CAS 148274-76-4 MG 1

MG 1
(CAS: 148274-76-4)

An α1 adrenergic receptor antagonist

CAS 6138-79-0 Triprolidine hydrochloride hydrate

Triprolidine hydrochloride hydrate
(CAS: 6138-79-0)

Triprolidine hydrochloride hydrate is a potent H1 histamine receptor antagonist. It is used in allergic rhinitis, urticaria and asthma. It is an over-the-counte...

CAS 93793-83-0 Roxatidine Acetate HCl

Roxatidine Acetate HCl
(CAS: 93793-83-0)

Roxatidine Acetate HCl is a specific and competitive histamin H2 receptor antagonist.

CAS 81161-17-3 Esmolol HCl

Esmolol HCl
(CAS: 81161-17-3)

Esmolol is a cardioselective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane ...

CAS 929622-08-2 Bavisant

(CAS: 929622-08-2)

Bavisant is a highly selective, orally active antagonist of the human H3 receptor. It is a novel mechanism of action, involving wakefulness and cognition. It ha...

Chemical Structure

CAS 5053-06-5 Fenspiride

Quick Inquiry

Verification code

Featured Items